Roopa Industries Ltd
Incorporated in 1985, Roopa Industries Ltd is in the business of TPP and its allied products[1]
- Market Cap ₹ 36.2 Cr.
- Current Price ₹ 46.1
- High / Low ₹ 72.0 / 40.0
- Stock P/E 18.8
- Book Value ₹ 23.2
- Dividend Yield 0.00 %
- ROCE 12.0 %
- ROE 12.1 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Company has a low return on equity of 10.8% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29 | 31 | 31 | 30 | 19 | 30 | 28 | 29 | 51 | 76 | 70 | 121 | 127 | |
| 29 | 29 | 31 | 28 | 22 | 28 | 26 | 26 | 48 | 72 | 66 | 117 | 122 | |
| Operating Profit | -0 | 2 | -1 | 2 | -3 | 2 | 2 | 3 | 3 | 4 | 4 | 4 | 6 |
| OPM % | -1% | 7% | -3% | 7% | -14% | 8% | 7% | 10% | 7% | 5% | 6% | 3% | 4% |
| 0 | -0 | 3 | 0 | 5 | 0 | 1 | 0 | 0 | 1 | 1 | 2 | 1 | |
| Interest | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 3 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | -2 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 3 |
| Tax % | 3% | 11% | 35% | 56% | -22% | 24% | 54% | 24% | 26% | 25% | 30% | 25% | |
| -2 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 2 | 2 | 2 | |
| EPS in Rs | -2.56 | 0.20 | 0.22 | 0.24 | 0.69 | 0.76 | 0.47 | 0.92 | 1.30 | 1.72 | 1.93 | 2.58 | 2.45 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 34% |
| 3 Years: | 33% |
| TTM: | 13% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | 40% |
| 3 Years: | 25% |
| TTM: | -7% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | 35% |
| 3 Years: | 1% |
| 1 Year: | -18% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 10% |
| 3 Years: | 11% |
| Last Year: | 12% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| Reserves | 1 | 1 | 1 | 2 | 2 | 3 | 3 | 4 | 5 | 6 | 8 | 10 | 10 |
| 8 | 8 | 8 | 11 | 16 | 15 | 14 | 13 | 12 | 19 | 26 | 33 | 36 | |
| 7 | 8 | 8 | 8 | 10 | 11 | 14 | 21 | 24 | 24 | 23 | 26 | 32 | |
| Total Liabilities | 24 | 26 | 25 | 29 | 35 | 36 | 38 | 46 | 49 | 57 | 65 | 76 | 87 |
| 8 | 8 | 7 | 7 | 6 | 6 | 11 | 10 | 10 | 10 | 9 | 8 | 8 | |
| CWIP | 0 | 0 | 0 | 0 | 2 | 4 | 0 | 0 | 1 | 1 | 1 | 1 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 16 | 18 | 18 | 22 | 27 | 26 | 28 | 36 | 39 | 46 | 55 | 68 | 78 | |
| Total Assets | 24 | 26 | 25 | 29 | 35 | 36 | 38 | 46 | 49 | 57 | 65 | 76 | 87 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1 | 1 | -1 | -5 | 4 | 2 | -1 | 2 | -0 | 2 | -7 | |
| -0 | -0 | 0 | -0 | 2 | -2 | 1 | 1 | 4 | -1 | 1 | 2 | |
| -0 | -0 | -1 | 2 | 2 | -2 | -3 | -1 | -5 | 2 | -2 | 5 | |
| Net Cash Flow | -0 | 0 | -0 | -0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 88 | 66 | 99 | 146 | 233 | 134 | 157 | 147 | 112 | 34 | 43 | 39 |
| Inventory Days | 94 | 143 | 70 | 139 | 217 | 171 | 256 | 409 | 140 | 109 | 168 | 121 |
| Days Payable | 118 | 132 | 100 | 122 | 177 | 123 | 219 | 280 | 86 | 42 | 96 | 56 |
| Cash Conversion Cycle | 65 | 77 | 69 | 164 | 273 | 182 | 194 | 277 | 166 | 101 | 116 | 104 |
| Working Capital Days | 15 | 32 | 69 | 114 | 214 | 108 | 104 | 114 | 37 | 1 | 10 | 36 |
| ROCE % | -4% | 10% | 10% | 10% | 6% | 9% | 9% | 8% | 10% | 13% | 12% | 12% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Export Share of Revenue Percentage (%) |
|
|||||||||||
| Debtors Turnover Ratio Ratio |
||||||||||||
| Number of Permanent Employees Number |
||||||||||||
| Power Consumption per kg of Production Rs/kg |
||||||||||||
| Total Production Volume kg |
||||||||||||
| Number of Primary Product Lines Number |
||||||||||||
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
17 Feb - Submission of newspaper clipping w.r.t publication of Unaudited Financial Results for the quarter and nine months ended 31 December 2025
-
Board Meeting Outcome for Submission Of Outcome Of Board Meeting And Unaudited Financial Results For The Quarter And Nine Months Ended 31 December 2025
14 Feb - Unaudited Q3/nine-months FY2026 results approved; Nov 3 Patancheru fire caused Rs.409.15 lakh losses.
- Submission Of Unaudited Financial Results For The Quarter And Nine Months Ended 31 December 2025 14 Feb
-
Board Meeting Intimation for Intimation Regarding Board Meeting To Be Held On Saturday, 14Th February, 2026 To Consider And Approve The Unaudited Financial Results For The 3Rd Quarter Ended On 31St December 2025
6 Feb - Board to approve Roopa Industries' unaudited Q3 results for quarter ended 31-Dec-2025 on 14 Feb 2026.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
17 Jan - Submission of Compliance Certificate under Reg 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 31/12/2026
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2][3][4]
RIL manufactures Bulk Drugs, Drug Intermediates, Nutraceuticals, and fine chemicals. It produces Active Pharmaceutical Ingredients such as Fluconazole, Sildenafil Citrate, Losartan Potassium and Triphenyl Phosphine (which goes into production of Cephalosporins, Statins etc.,) and Nutraceuticals such as Glucosamine salts.
Its products are used in chemical and pharmaceutical industry and supplied globally